Leerink Swann Downgrades Gilead Sciences to Market Perform

Brokerage firm Leerink Swann Downgrades its rating on Gilead Sciences(NASDAQ:GILD). The shares have been rated Market Perform. Previously, the analysts had a Outperform rating on the shares. The rating by Leerink Swann was issued on Sep 27, 2016.

In a different note, Berenberg said it Initiates Coverage on Gilead Sciences, according to a research note issued on Sep 22, 2016. The shares have been rated ‘Buy’ by the firm. On Sep 14, 2016, Credit Suisse said it Maintains its rating on Gilead Sciences. In the research note, the firm Lowers the price-target to $115.00 per share. The shares have been rated ‘Outperform’ by the firm. Berenberg said it Initiates Coverage on Gilead Sciences, according to a research note issued on Sep 12, 2016. The shares have been rated ‘Buy’ by the firm. On Sep 6, 2016, Jefferies said it Upgrades its rating on Gilead Sciences. The shares have been rated ‘Buy’ by the firm. On Aug 31, 2016, Jefferies said it Maintains its rating on Gilead Sciences. In the research note, the firm Lowers the price-target to $93.00 per share. The shares have been rated ‘Hold’ by the firm. On Jul 29, 2016, Argus Research said it Downgrades its rating on Gilead Sciences. The shares have been rated ‘Hold’ by the firm.

Gilead Sciences (GILD) made into the market gainers list on Fridays trading session with the shares advancing 1.62% or 1.26 points. Due to strong positive momentum, the stock ended at $79.12, which is also near the day’s high of $79.63. The stock began the session at $78.06 and the volume stood at 1,10,31,540 shares. The 52-week high of the shares is $111.11 and the 52 week low is $76.67. The company has a current market capitalization of $104,411 M and it has 1,31,96,58,490 shares in outstanding.

Gilead Sciences(GILD) last announced its earnings results on Jul 25, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $7.78B. Analysts had an estimated revenue of $7.79B. Earnings per share were $3.08. Analysts had estimated an EPS of $3.00.

Several Insider Transactions has been reported to the SEC. On Sep 26, 2016, Gregg H Alton (EVP Comm&Acs ALA, Corp&Med Aff) sold 5,000 shares at $81.84 per share price.Also, On Sep 8, 2016, John F Milligan (President and CEO) sold 70,000 shares at $77.74 per share price.On Sep 6, 2016, John C Martin (Executive Chairman) sold 100,000 shares at $77.82 per share price, according to the Form-4 filing with the securities and exchange commission.

Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Company’s primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Company’s HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Company’s oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Gilead Sciences - Is it time to Sell?

Top Brokerage Firms are advising their investors on Gilead Sciences. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.